

Acarix Interim report January-March 2020



Continued focus on strategic key priorities

First quarter 2020 compared with same period 2019

- During the first quarter, one CADScor®System was rented (5 systems were sold) and 370 (640) disposable patches were sold. Additionally, 240 patches were delivered for clinical trials.
- Revenue amounted to 121 kSEK (299), with gross profit of 109 kSEK (209) and a gross margin of 90 percent (70).
- Operational costs amounted 10,904 kSEK (13,038).
- Result before tax amounted to -10,815 kSEK (-12,822).
- Net cash flow from operating activities amounted to -8,575 kSEK (-13,101).
- Cash at the end of the period was 45,019 kSEK (51,581).
- Basic earnings per share amounted to -0.21 SEK (-0.56). No dilution arose.

Events in the first quarter, 2020

- On January 14, 2020, the company announced the first commercial usage of the CADScor®System in the UK. Dr Amrit Takhar and his team at Wansford and Kingscliffe Practice, near Peterborough, UK, is the first clinic in the UK to use the unique CADScor technology to assess patients suffering from stable chest pain.
- On February 18, 2020, the company announced the initiation of the randomized, multi-center clinical study FILTER-SCAD to examine the cost effectiveness and safety of adding the CADScor®System as a rule-out test in patients referred with symptoms suggestive of stable coronary artery disease. In the FILTER-SCAD study, 2,000 patients referred on suspected stable coronary disease are to be consecutively enrolled at four hospitals in Denmark and Lund's University Hospital in Sweden.
- On March 12, 2020, the company received encouraging feedback from the German authorities, the Federal Joint Committee, G-BA, on its submission for reimbursement of the CADScor®System in Germany. "They conclude that the CADScor®System represents a promising technology and they see a potential fit with the German health care system which is positive," said Per Persson, CEO Acarix. "Now, our submission process will proceed to the next step whereby G-BA will review Acarix's latest updates in clinical evidence and ongoing studies, or as an alternative, suggest a local German confirmatory study. We are expecting additional comments by mid-year."

- During the first quarter of 2020, the Covid-19 pandemic broke out and the consequences of the outbreak have had a negative impact on Acarix since March, and there is a risk that this could lead to a negative financial impact on the Group. At Acarix, we are working to ensure that the business continues to operate to the best of our ability, but also with a focus of our employees' health. We do this primarily through a call to the company's staff to work from home and a travel ban. In our assessment of the immediate effects, we can conclude that the patient recruitment in our ongoing clinical studies The Filter Scad Study and the Dan-NICAD II study have stopped which may delay the completion of the studies. In addition, the company has submitted a DeNovo application to the FDA (American Food and Drug Administration) for product approval prior to the launch of the CADScor®System in the US market. There is a risk that the approval process will be delayed.

With regard to the reimbursement process in Germany, it is ongoing with the G-BA (Federal Joint Committee). At the beginning of 2020, we received positive feedback from G-BA, which expected to return with further information in mid-2020. There is a risk that G-BA's feedback may be delayed.

Since most hospitals, health centers and even private clinics have restricted access to commercial operations, sales and markets are also affected to a great extent as long as the Covid-19 situation remains. Both international and national congresses and educational meetings have been suspended or postponed until the latter part of the year. All in all, this means that a large part of our commercial activities are affected by the corresponding shift as long as the Covid-19 crisis lasts. However, given the uncertain situation at present, it is not possible to estimate the full potential impact for Acarix.

Events after March 31, 2020

- On May 11, 2020, the company announced that the last patient was included in the exploratory SEISMO study, which is evaluating the possibility of developing an early heart failure detection algorithm.

The total amount in tables and statements might not always summarize as there are rounding differences. The aim is to have each line item corresponding to the source and it might therefore be rounding differences in the total.

CEO Message

During the quarter we have kept focus on our priorities along with managing the impact from the global Covid-19 situation. We have been in continued dialogue with both the US Food and Drug Administration, FDA, for our US market approval, and the German G-BA for the German reimbursement process. The FDA have sent primary responses with relevant and related comments and questions to our initial submission which we are now processing accordingly. We are consolidating all responses and we are confident that we will be able to submit our feedback timely and the process are within our expectations.

The G-BA process is also running according to their estimated guiding and we await their initial feedback by mid-year. With that in mind both the FDA and G-BA have indicated that the pandemic could lead to delays, and we are focusing on the deliverables we can control from our side.

In a wider perspective, we can see indications in the market pointing towards non-invasive and less complex methods being reinforced by the pandemic. Patients and physicians are asking for technologies that are non-invasive, easy to use, logistically smart (no transportation, no facility remake) and reliable. The CADScor®System is uniquely positioned to meet these needs. With its rule-out capabilities, the CADScor®System may contribute to lessen the burden on the healthcare system by allowing less patients to be referred to the hospitals from primary care settings and at the same time give physicians and patients earlier clarity about the patients' medical status.

For a couple of months, we have collected data from over 1,000 patients at four independent clinics in Germany and Austria to see how well the CADScor® performs in real life practice. The material is currently being analyzed, but initial data indicate that results are in line with previous clinical results (DANICAD I). Strong data from a real, actual use of the CADScor®System are of great importance in the work of commercializing our technology. The analysis is expected to be completed later this summer.

We recently enrolled the last patient in the exploratory clinical heart failure trial, SEISMO. The study included 199 patients at two sites in Denmark. In parallel with our core focus on coronary artery disease we are exploring potential application for which our unique technology might make a difference. Heart Failure is an area that has a huge potential and we assess the opportunity of helping patients with early detection based on our acoustic technology. The initial results are expected in the second half of 2020.



The Covid-19 pandemic has made its mark for everyone and for Acarix this has not been an exception. In order to adapt to the new situation, we acted fast and identified areas that would allow for relevant savings without jeopardizing our key priorities, such as our two most important studies the DANICAD II and the FILTER Study as well as the application processes towards the FDA as well as the G-BA. As a result, we have made adjustments to the organization, adopted our other investment priorities and reduced compensation for most employees as well for the Board of Directors.

I would like to take the opportunity to thank our customers, both new and long shareholders and our Board of Directors for their support.

Sincerely,
Per Persson
Chief Executive Officer

Financial Report

Revenues and gross margin

First quarter

One CADScor®System were rented to a new customer in Luxembourg and 370 disposable patches were sold during the quarter. Additionally, 240 disposable patches were delivered for our ongoing clinical trials. During the corresponding period last year, five CADScor®Systems and 640 disposable patches were sold. Sales and marketing activities have been affected during the quarter due to the covid-19 situation, which is reflected in our sales and market activities.

Gross profit for the quarter amounted to 109 kSEK, which corresponded to a gross margin of 90 percent, compared with 70 percent in the same period last year. The reason for a higher gross margin compared to the same period last year is the higher share of revenues related to disposable patches.

Expenses

First quarter

Total operating expenses (R&D and sales/administration expenses) for the first quarter amounted to 10,904 kSEK, compared with 13,038 kSEK in the corresponding period last year. Sales and administrative expenses amounted to 6,373 (7,792) kSEK in the quarter, of which 2,655 (4,273) kSEK related to sales/marketing expenses. Research and development costs amounted to 4,531 (5,245) kSEK. and are mainly generated from ongoing clinical trials.

Result

First quarter

During the quarter, the Group reported an operating loss of -10,795 kSEK compared to -12,829 kSEK during the corresponding period last year. Depreciation during the quarter amounted to 1,011 kSEK, distributed between capitalized development costs of 583 kSEK, patent costs of 67 kSEK, depreciation of leasing assets of 343 kSEK and tangible assets of 17 kSEK. The net loss for the quarter amounted to SEK -10,815 kSEK compared to -12,797 kSEK during the corresponding period last year. Earnings per share before dilution were SEK -0.21 for the first quarter compared to SEK -0.56 for the corresponding period last year. There were no dilution effects.

Intangible assets

Development costs related to the CADScor®System have been capitalized since August 2015. Capitalization ceased when the product was launched on the market during the second quarter of 2017. As of March 31, 2020, capitalized development costs amounted to 17,376 kSEK. The carrying amount including capitalized development costs and acquired rights as of March 31, 2020 amounted to 22,176 kSEK.

Equity

As of March 31, 2020, consolidated equity amounted to 67,502 kSEK compared to 75,448 kSEK on March 31, 2019.

During the last quarter, a rights issue was carried out. The share capital increased by 28,667 kSEK to SEK 51,694 kSEK.

The rights issue contributed 34,548 kSEK to the company after issue costs.

Cash Flow

First quarter

The total outflow for the period amounted to -9,124 kSEK compared with an outflow of -13,460 kSEK during the corresponding period last year. The effect from working capital amounted to 1,012 kSEK compared with -1,283 kSEK in the corresponding period last year.

In the fourth quarter 2019, the funds were increased by a rights issue providing a net capital of 34,548 kSEK.

Parent Company

The Parent Company's operations are primarily focused on Group wide administration and management and have during the quarter recognized 2,190 kSEK (3,135) as management fees. The company reported a net loss for the quarter of -4,420 kSEK (-6,519) including write-down of shares in subsidiary amounting to -2,114 kSEK (-4,236).

From second quarter 2018 onwards, shareholder contributions covering losses in the wholly owned subsidiaries have been recognized in the Parent Company's profit and loss and not as a financial fixed asset. Participation in subsidiaries on December 31 amounted to 42,178 kSEK (42,178).

The Parent Company's cash and cash equivalents at the end of the period amounted to 42,325 kSEK compared to 50,884 in the year-earlier period.

Share information

The share has been trading on Nasdaq First North Growth Market Stockholm with the ticker symbol ACARIX and ISIN code SE0009268717 since December 19, 2016 and the shares are listed under the Premier segment. As of March 31, 2020, the number of shares in the company amounted to 51,694,043 (23,027,376).

Shareholder register March 31, 2020	Number of shares	Votes and capital
Sunstone LSV Fund II K/S	4,749,081	9.2%
SEED Capital DK II K/S	4,749,081	9.2%
Försäkringsaktiebolaget Avanza Pension	3,200,629	6.2%
Puhua Jingxin	2,654,259	5.1%
SHB, Copenhagen Branch	2,023,290	3.9%
Formue Nord Markedsneutral A/S	1,714,772	3.3%
Danska Bank International S.A	1,702,614	3.3%
Coloplast A/S	1,683,072	3.3%
Nordnet Pensionsförsäkring AB	1,666,890	3.2%
Mikael Lönn	1,366,930	2.6%
Other shareholders	26,183,425	50.6%
Total	51,694,043	100.0%

Auditor's review

This Interim report has not been reviewed by the company's auditor.

Certified Adviser

Acarix's Certified Adviser on Nasdaq First North is Wildeco Ekonomisk Information AB, tel +46 8 545 271 00 or info@wildeco.se.

Financial calendar	Date
Annual General Meeting	May 14, 2020
Interim Report, second quarter	August 20, 2020
Interim Report, third quarter	November 12, 2020

For more information, please contact

Per Persson, CEO
Email: per.persson@acarix.com
Ph: +46 736 005 990

Christian Lindholm, CFO
Email: christian.lindholm@acarix.com
Ph: +46 705 118 333

Group – Consolidated statement of income

kSEK	Note	Jan-Mar 2020	Jan-Mar 2019	Year 2019
Revenue	7	121	299	1,857
Cost of goods sold		-12	-90	-427
Gross profit		109	209	1,430
Research and development costs		-4,531	-5,245	-20,282
Sales, general and administrative costs		-6,373	-7,793	-27,591
Operating result		-10,795	-12,829	-46,444
Financial income		1	36	103
Financial costs		-21	-29	-94
Profit before tax		-10,815	-12,822	-46,434
Tax		-	25	-25
Net loss for the period		-10,815	-12,797	-46,459
Net income attributable to Parent Company's shareholders		-10,815	-12,797	-46,459
Basic earnings per share (SEK) ^{1), 2)}		-0,21	-0.56	-1.83
Diluted earnings per share (SEK)		-0,21	-0.56	-1.83
Average number of shares, thousands		51,694	23,027	27,805

¹⁾ No dilution effects arose

²⁾ EPS – Net profit for the period, attributable to shareholders of the Parent Company, divided by average number of shares outstanding

Group – Consolidated statement of comprehensive income

kSEK	Jan-Mar 2020	Jan-Mar 2019	Year 2019
Net loss for the period after tax	-10,815	-12,797	-46,459
Items that may be reclassified to profit or loss			
Foreign currency translation adjustment	1,714	368	637
Other comprehensive income for the period, net of tax	1,714	368	637
Total comprehensive income for the period, net of tax	-9,102	-12,429	-45,822
Total comprehensive income attributable to:			
Owners of Acarix	-9,102	-12,429	-45,822

Group – Consolidated statement of financial position

kSEK	Note	Mar 31, 2020	Mar 31, 2019	Dec 31, 2019
Assets				
<i>Tangible assets</i>				
Lease rights		1,822	1,883	881
Tangible assets		197	-	-
Total tangible assets		2,019	1,883	881
<i>Intangible assets</i>				
Acquired rights		4,800	4,779	4,584
Development projects, capitalized		17,376	18,628	16,924
Total intangible assets	8	22,176	23,407	21,508
Deferred tax assets		-	25	-
Total fixed assets		22,176	25,315	22,389
<i>Current assets</i>				
Inventory		3,996	3,327	3,052
Accounts receivables		424	830	1,108
Other receivables		2,070	2,602	2,688
Cash and cash equivalents		45,018	51,581	53,747
Total current assets		51,506	58,340	60,594
Total assets		75,701	83,655	82,983
Shareholders' equity and liabilities				
<i>Equity</i>				
Share capital and share premium		430,592	396,044	430,592
Other reserves		4,227	2,245	2,514
Retained earnings		-367,317	-322,841	-356,502
Total equity		67,502	75,448	76,602
<i>Long term liabilities</i>				
Lease debt		1,003	300	72
Total long term liabilities		1,003	300	72
<i>Current liabilities</i>				
Lease debt		795	1,466	694
Accounts payable		1,909	1,643	1,781
Other liabilities		4,492	4,798	3,834
Total current liabilities		7,196	7,907	6,309
Total equity and liabilities		75,701	83,655	82,983

Group – Consolidated statement of changes in shareholders' equity

	Share capital	Share premium	Other reserves	Retained earnings	Total shareholders equity
As at January 1, 2020	51 694	378 898	2 514	-356 502	76 602
Profit/loss for the period	-	-	-	-10,815	-10,815
Other comprehensive income:					
Foreign exchange rate adjustment	-	-	1,714	-	1,714
Total comprehensive income	-	-	4,227	-367,317	67,502
At March 31, 2020	51,694	378,898	4227	-367,317	67502
As at January 1, 2019	23,027	373,017	1,877	-310,044	87,878
Profit/loss for the period	-	-	-	-12,797	-12,797
Other comprehensive income:					
Foreign exchange rate adjustment	-	-	368	-	368
Total comprehensive income	23,027	373,017	2,245	-322,841	75,448
At March 31, 2019	23,027	373,017	2,245	-322,841	75,448

Group – Consolidated statement of cash flows

kSEK	Jan-Mar 2020	Jan-Mar 2019	Year 2019
Operating activities			
Operating result	-10,795	-12,829	-46,444
Adjustment for depreciation	1,011	1,002	4,115
Taxes received	-	-	-
Financial items	-19	7	9
Cash-flow before change of working capital	-9,803	-11,820	-42,320
<i>Working capital adjustments:</i>			
Change in inventory	-1,159	-702	-426
Change in receivables and prepayments	1,930	558	-428
Change in trade and other payables	240	-1,139	-1,359
Total change in working capital	1,012	-1,283	-2,213
Cash-flow from operations	-8,790	-13,101	-44,533
Cash-flow from operating activities	-8,575	-13,101	-44,533
Financing activities			
Amortization of lease debt	-334	-359	-1,515
Rights issue	-	-	34,548
Cash-flow from financing activities	-334	-359	33,033
Cash flow for the period	-9,124	-13,460	-11,500
Currency translation differences	396	22	238
Cash and cash equivalents, beginning of period	53,747	65,019	65,019
Cash and cash equivalents, end of period	45,018	51,581	53,747

Parent Company income statement

kSEK	Note	Jan-Mar 2020	Jan-Mar 2019	Year 2019
Other revenue		2,190	3,135	7,967
Sales, general and administrative costs		-4,509	-5,449	-20,259
Operating result		-2,319	-2,314	-12,292
Profit/Loss from shares in group companies		-2,114	-4,236	-33,654
Financial income		13	31	92
Financial expense		-	-	-1
Result before tax		-4,420	-6,519	-45,855
Tax		-	-	-
Net loss for the period		-4,420	-6,519	-45,855
Net result attributable to Parent Company's shareholder		-4,420	-6,519	-45,855

Parent Company balance sheet

kSEK	Note	Mar 31, 2020	Mar 31, 2019	Dec 31, 2019
Assets				
<i>Financial assets</i>				
Participation in subsidiaries		42,178	42,178	42,178
Total financial assets		42,178	42,178	42,178
<i>Current assets</i>				
Other receivables		2,990	3,876	1,163
Cash and cash equivalents		42,325	50,884	48,243
Total current assets		45,315	54,760	49,406
Total assets		87,493	96,938	91,584
Shareholders' equity and liabilities				
<i>Equity</i>				
Share capital		51,694	23,027	51,694
Other capital contribution		162,793	156,912	162,793
Retained earnings		-130,214	-86,458	-125,794
Total equity		84,274	93,481	88,693
<i>Current liabilities</i>				
Accounts payable		406	242	666
Other liabilities		2,814	3,215	2,224
Total current liabilities		3,220	3,457	2,890
Total equity and liabilities		87,493	96,938	91,584

Parent Company statement of changes in equity

kSEK	Share capital	Other capital contribution	Retained earnings	Total shareholders' equity
As at January 1, 2020	51,694	162,793	-125,794	88,693
Net loss for the period	-	-	-4,420	-4,420
Total comprehensive income	-	-	-4,420	-4,420
Change in shareholders' equity	-	-	-4,420	-4,420
At March 31, 2020	51,694	162,793	-130,214	84,274
As at January 1, 2019	23,027	156,912	-79,939	100,000
Net loss for the period	-	-	-6,519	-6,519
Total comprehensive income	-	-	-6,519	-6,519
Change in shareholders' equity	-	-	-6,519	-6,519
At March 31, 2019	23,027	156,912	-86,458	93,481

Notes to the interim consolidated financial statements

NOTE 1 CORPORATE INFORMATION

Company information

Acarix AB (559009-0667) is a limited liability company incorporated and domiciled in Malmö, Sweden. The registered office is located at World Trade Center Malmö, Skeppsgatan 19, 211 11 Malmö, Sweden. Acarix's main activities are to develop, produce and market a new cardiovascular diagnostic method and similar equipment for the same and related services.

The Acarix Group consist of:

Acarix A/S	The main operating company	Incorporated and located in Denmark
Acarix GmbH	Supporting sales on the German market	Incorporated and located in Germany
Acarix GmbH	Supporting sales on the Austrian market	Incorporated and located in Austria
Acarix China ApS	Supporting Chinese approval process	Incorporated and located in Denmark
Acarix Incentive AB		Incorporated and located in Sweden

NOTE 2 BASIS OF PREPARATION

The interim report for the Group and Parent Company comprises summary consolidated financial statements for Acarix AB (publ). The interim consolidated financial statements include the Company's wholly-owned subsidiaries according to above specification.

NOTE 3 ACCOUNTING POLICIES

Accounting policies

The consolidated report has been prepared in accordance with International Financial Reporting Standards (IFRS) and IAS 34, Interim Financial Reporting. Amendments to existing standards, new interpretations and new standards that came into effect as of January 1, 2019 did not affect the Groups reporting as of December 31, 2019, except for IFRS 16.

Acarix continues to apply the same accounting principles and valuation methods as those described in the most recent Annual Report. The Parent Company report is prepared in accordance with RFR 2, Accounting for Legal Entities, the Swedish Annual Accounts Act and accounting principles and the valuation methods as those described in the most recent Annual Report.

NOTE 4 SIGNIFICANT ACCOUNTING ESTIMATES, JUDGMENTS AND ASSUMPTIONS

In preparing the interim report, certain provisions under IFRS require management to make judgments, which may significantly impact the Group's financial statements. For additional descriptions of significant judgments and estimates, refer to note 4 in the annual report 2019.

NOTE 5 RISK MANAGEMENT

The Acarix Group is exposed to business and financial risks through its operations. These risks have been described at length in the Company's annual report 2019. In addition to the risks described in these documents, no additional significant risks have been identified.

NOTE 6 RELATED PARTIES

Related parties comprise the members of the Board of Directors and other senior executives. Apart from remuneration of the Board of Directors, transactions to market price were recognized with related parties during the year.

Consultancy fee to member of Board of Directors 2020

kSEK	Q1	Q2	Q3	Q4	Year
No consultancy fees have been paid for in 2020	-				
Total	-				

Consultancy fee to member of Board of Directors 2019

kSEK	Q1	Q2	Q3	Q4	Year
Werner Braun (Chairman)	-	66	-	-	66
Total	-	66	-	-	66

NOTE 7 REVENUE RECOGNITION

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured, regardless of when the payment is received. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duty. The specific recognition criteria described below must also be met before revenue is recognized.

Sale of goods

Revenue from the sale of goods is recognized when the significant control of ownership of the goods have passed

to the buyer, usually on delivery of the goods. Revenue from the sale of goods is measured at the fair value of the consideration received or receivable, net of returns and allowances, trade discounts and volume rebates.

Invoiced sales per country, kSEK	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1-Q4 2020
Germany	96				
Sweden	-				
Denmark	-				
Austria	-				
Other	25				
Total	121				

Invoiced sales per country, kSEK	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1-Q4 2019
Germany	203	225	120	183	731
Sweden	96	29	-	-	125
Denmark *	-	410	-	398	808
Austria	-	-	-	-	-
Other	-	-	-	193	193
Total	299	664	120	774	1,857
Total excluding deliveries to clinical trials	299	254	120	376	1,049

* deliveries to clinical trials

NOTE 8 INTANGIBLE ASSETS

Development projects are related to the development of the CADScor®System (acoustic cardiovascular diagnostics), which records heart sounds and murmurs for calculating a patient's specific score in order to determine the patient's risk of coronary artery disease. During the second quarter 2017, the CADScor®System was introduced on the market and the first sales orders were recognized. Capitalization of development costs ceased when the product was ready to

launch on the market and amortization of capitalized development costs commenced. Management estimates the useful life of development projects to be 10 years. These assets are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount exceeds the recoverable amount. Development projects have been tested for impairment in December 2019.

Group, 2019, kSEK	Acquired rights	Development costs	Total
Cost at January 1, 2020	6,054	22,819	28,873
Foreign currency translation adjustment	332	1,426	1,758
Cost at March 31, 2020	6,387	24,245	30,632
Amortization and impairment at January 1, 2020	-1,470	-5,895	-7,365
Amortization	-67	-583	-650
Foreign currency translation adjustment	-49	-392	-441
Amortization and impairment losses at March 31, 2020	-1,586	-6,869	-8,456
Carrying amount at March 31, 2020	4,800	17,376	22,176

Group, 2019, kSEK	Acquired rights	Development costs	Total
Cost at January 1, 2019	5,975	22,480	28,456
Foreign currency translation adjustment	77	330	407
Cost at March 31, 2019	6,052	22,810	28,862
Amortization and impairment at January 1, 2019	-1,200	-3,559	-4,759
Amortization	-65	-565	-630
Foreign currency translation adjustment	-8	-58	-66
Amortization and impairment losses at March 31, 2019	-1,273	-4,182	-5,455
Carrying amount at March 31, 2019	4,779	18,628	23,407

Affirmation

This interim report has been prepared in accordance with International Accounting Standard (IAS) 34 “Interim Financial Reporting” and in accordance with the Swedish Annual Accounts Act. With respect to the Parent Company, this interim report has been prepared in accordance with the Swedish Annual Accounts Act and in compliance with

RFR2, Accounting for Legal Entities. The Board of Directors and the CEO certify that this interim report presents a true and fair overview of the Group’s and the Parent Company’s operations, financial position and results of operations, and describes the significant risks and uncertainties facing the Parent Company and the companies belonging to the Group.

Malmö, May 14, 2020

EXECUTIVE MANAGEMENT

Per Persson
CEO

BOARD OF DIRECTORS

Dr. Werner Braun
Chairman of the Board

Paolo Raffaelli
Board Member

Johanne Braendgaard
Board Member

Claus Andersson
Board Member

Hong Yun Fei
Board Member

Ulf Rosén
Board Member

The information disclosed in this year-end report is mandatory for Acarix AB (publ) to publish pursuant to the EU Market Abuse Regulation.
This information was submitted through the agency of the CEO, May 14, 2020 at 8:00 am (CET).

Acarix AB (publ)
World Trade Center Malmö
Skeppsgatan 19
SE-211 11 Malmö
Sweden

Phone: +46 10 471 58 02
Mail: info@acarix.com
www.acarix.com

